The University of Chicago Header Logo

Connection

Kenneth Gordon to Antibodies, Monoclonal, Humanized

Back to Details
This is a "connection" page, showing publications Kenneth Gordon has written about Antibodies, Monoclonal, Humanized.
Kenneth Gordon
Connection Strength
7.550
Antibodies, Monoclonal, Humanized
  1. Effect of spesolimab on sustained disease control in patients with generalized pustular psoriasis: Post hoc analysis of the EFFISAYIL 2 study. J Am Acad Dermatol. 2025 Jun; 92(6):1235-1242.
    View in: PubMed
    Score: 0.589
  2. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 07 01; 158(7):735-744.
    View in: PubMed
    Score: 0.489
  3. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021 02 06; 397(10273):475-486.
    View in: PubMed
    Score: 0.444
  4. Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study. Am J Clin Dermatol. 2020 Dec; 21(6):881-890.
    View in: PubMed
    Score: 0.438
  5. Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials. J Dermatolog Treat. 2022 Feb; 33(1):219-228.
    View in: PubMed
    Score: 0.421
  6. Sustained and continuously improved efficacy of tildrakizumab in patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2020 Dec; 31(8):763-768.
    View in: PubMed
    Score: 0.399
  7. Guselkumab Efficacy after Withdrawal Is Associated with Suppression of Serum IL-23-Regulated IL-17 and IL-22 in Psoriasis: VOYAGE 2 Study. J Invest Dermatol. 2019 12; 139(12):2437-2446.e1.
    View in: PubMed
    Score: 0.396
  8. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014 Dec; 71(6):1176-82.
    View in: PubMed
    Score: 0.285
  9. New and emerging therapies in psoriasis. Semin Cutan Med Surg. 2014 Mar; 33(2 Suppl 2):S37-41.
    View in: PubMed
    Score: 0.275
  10. Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2013 Dec; 169(6):1337-41.
    View in: PubMed
    Score: 0.270
  11. Rationale and early clinical data on IL-17 blockade in psoriasis. Expert Rev Clin Immunol. 2013 Jul; 9(7):677-82.
    View in: PubMed
    Score: 0.262
  12. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol. 2012 Feb; 66(2):241-51.
    View in: PubMed
    Score: 0.229
  13. Bimekizumab Complete Clearance of Both Skin and Nail Psoriasis: Comparative Efficacy in Phase III/IIIb Studies. Am J Clin Dermatol. 2025 Nov; 26(6):967-979.
    View in: PubMed
    Score: 0.152
  14. Targeting the IL-36 receptor with spesolimab mitigates residual inflammation and prevents generalized pustular psoriasis flares. J Clin Invest. 2025 Sep 02; 135(17).
    View in: PubMed
    Score: 0.151
  15. Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension trial. J Am Acad Dermatol. 2025 Sep; 93(3):644-653.
    View in: PubMed
    Score: 0.149
  16. Bimekizumab for the treatment of psoriasis. Immunotherapy. 2024 04; 16(7):431-446.
    View in: PubMed
    Score: 0.138
  17. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021 02 06; 397(10273):487-498.
    View in: PubMed
    Score: 0.111
  18. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020 Apr; 82(4):936-945.
    View in: PubMed
    Score: 0.102
  19. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study. J Eur Acad Dermatol Venereol. 2020 Feb; 34(2):301-309.
    View in: PubMed
    Score: 0.102
  20. Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Qual Life Res. 2020 Feb; 29(2):369-380.
    View in: PubMed
    Score: 0.102
  21. Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: An analysis from VOYAGE 1 and VOYAGE 2. J Dermatol. 2019 Dec; 46(12):1141-1152.
    View in: PubMed
    Score: 0.101
  22. IL-23 inhibitors for moderate-to-severe psoriasis. Semin Cutan Med Surg. 2018 Sep; 37(3):158-162.
    View in: PubMed
    Score: 0.094
  23. Anxiety and depression in patients with moderate-to-severe psoriasis and comparison of change from baseline after treatment with guselkumab vs. adalimumab: results from the Phase 3 VOYAGE 2 study. J Eur Acad Dermatol Venereol. 2018 Nov; 32(11):1940-1949.
    View in: PubMed
    Score: 0.093
  24. Efficacy and safety of ixekizumab over 4 years of open-label treatment in a phase 2 study in chronic plaque psoriasis. J Am Acad Dermatol. 2018 Aug; 79(2):294-301.e6.
    View in: PubMed
    Score: 0.091
  25. Efficacy of guselkumab in subpopulations of patients with moderate-to-severe plaque psoriasis: a pooled analysis of the phase III VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2018 01; 178(1):132-139.
    View in: PubMed
    Score: 0.089
  26. Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. J Eur Acad Dermatol Venereol. 2017 Jun; 31(6):1004-1013.
    View in: PubMed
    Score: 0.085
  27. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar; 76(3):418-431.
    View in: PubMed
    Score: 0.084
  28. Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis. N Engl J Med. 2016 Jul 28; 375(4):345-56.
    View in: PubMed
    Score: 0.080
  29. Effect of Ixekizumab Treatment on Work Productivity for Patients With Moderate-to-Severe Plaque Psoriasis: Analysis of Results From 3 Randomized Phase 3 Clinical Trials. JAMA Dermatol. 2016 06 01; 152(6):661-9.
    View in: PubMed
    Score: 0.080
  30. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015 Oct; 373(14):1318-28.
    View in: PubMed
    Score: 0.077
  31. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. N Engl J Med. 2015 Jul 09; 373(2):136-44.
    View in: PubMed
    Score: 0.075
  32. A high level of clinical response is associated with improved patient-reported outcomes in psoriasis: analyses from a phase 2 study in patients treated with ixekizumab. J Eur Acad Dermatol Venereol. 2016 May; 30(5):864-5.
    View in: PubMed
    Score: 0.074
  33. Impact of brodalumab treatment on psoriasis symptoms and health-related quality of life: use of a novel patient-reported outcome measure, the Psoriasis Symptom Inventory. Br J Dermatol. 2014 Mar; 170(3):705-15.
    View in: PubMed
    Score: 0.069
  34. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol. 2013 Dec; 27(12):1535-45.
    View in: PubMed
    Score: 0.063
  35. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis. 2013 Apr; 72(4):517-24.
    View in: PubMed
    Score: 0.060
  36. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol. 2012 Feb; 132(2):304-14.
    View in: PubMed
    Score: 0.058
  37. Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): results from analyses of infections and malignancy from pooled phase II and III clinical trials. J Am Acad Dermatol. 2012 May; 66(5):742-51.
    View in: PubMed
    Score: 0.058
  38. Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis. Semin Cutan Med Surg. 2010 Mar; 29(1):48-52.
    View in: PubMed
    Score: 0.052
  39. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol. 2006 Oct; 55(4):598-606.
    View in: PubMed
    Score: 0.041
  40. The treatment of psoriasis and psoriatic arthritis: an interdisciplinary approach. J Am Acad Dermatol. 2006 Mar; 54(3 Suppl 2):S85-91.
    View in: PubMed
    Score: 0.039
  41. The tumour necrosis factor-alpha inhibitor adalimumab rapidly reverses the decrease in epidermal Langerhans cell density in psoriatic plaques. Br J Dermatol. 2005 Nov; 153(5):945-53.
    View in: PubMed
    Score: 0.039
  42. Incidence of infection during efalizumab therapy for psoriasis: analysis of the clinical trial experience. Clin Ther. 2005 Sep; 27(9):1317-28.
    View in: PubMed
    Score: 0.038
  43. Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials. Br J Dermatol. 2024 03 15; 190(4):477-485.
    View in: PubMed
    Score: 0.034
  44. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther. 2004; 17(5):427-31.
    View in: PubMed
    Score: 0.034
  45. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA. 2003 Dec 17; 290(23):3073-80.
    View in: PubMed
    Score: 0.034
  46. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023 10 28; 402(10412):1541-1551.
    View in: PubMed
    Score: 0.033
  47. Five-year maintenance of clinical response and health-related quality of life improvements in patients with moderate-to-severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2. Br J Dermatol. 2021 12; 185(6):1146-1159.
    View in: PubMed
    Score: 0.029
  48. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Br J Dermatol. 2020 06; 182(6):1348-1358.
    View in: PubMed
    Score: 0.026
  49. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019 Apr; 80(4):1029-1072.
    View in: PubMed
    Score: 0.024
  50. Efficacy of Guselkumab Compared With Adalimumab and Placebo for Psoriasis in Specific Body Regions: A Secondary Analysis of 2 Randomized Clinical Trials. JAMA Dermatol. 2018 06 01; 154(6):676-683.
    View in: PubMed
    Score: 0.023
  51. Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018 08; 179(2):320-328.
    View in: PubMed
    Score: 0.023
  52. Measurement Properties of the Psoriasis Symptom Inventory Electronic Daily Diary in Patients with Moderate to Severe Plaque Psoriasis. Value Health. 2017 09; 20(8):1174-1179.
    View in: PubMed
    Score: 0.022
  53. Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin-12/23 monoclonal antibody, briakinumab, in moderate to severe psoriasis. J Eur Acad Dermatol Venereol. 2013 Oct; 27(10):1252-61.
    View in: PubMed
    Score: 0.016
  54. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol. 2012 Apr; 166(4):861-72.
    View in: PubMed
    Score: 0.015
  55. An update on the long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012 Mar; 11(3):300-12.
    View in: PubMed
    Score: 0.015
  56. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. JAMA. 2011 Aug 24; 306(8):864-71.
    View in: PubMed
    Score: 0.014
  57. Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial. J Am Acad Dermatol. 2011 Feb; 64(2):263-74.
    View in: PubMed
    Score: 0.014
  58. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010 Sep; 63(3):448-56.
    View in: PubMed
    Score: 0.013
  59. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010 Sep; 63(3):457-65.
    View in: PubMed
    Score: 0.013
  60. Rethinking eligibility creep. J Am Acad Dermatol. 2008 Jul; 59(1):165-7; author reply 167.
    View in: PubMed
    Score: 0.012
  61. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May; 58(5):826-50.
    View in: PubMed
    Score: 0.011
  62. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May; 58(5):851-64.
    View in: PubMed
    Score: 0.011
  63. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008 Jan; 58(1):106-15.
    View in: PubMed
    Score: 0.011
  64. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation. J Dermatol Sci. 2007 Nov; 48(2):87-101.
    View in: PubMed
    Score: 0.011
  65. Impact of adalimumab treatment on patient-reported outcomes: results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis. J Dermatolog Treat. 2007; 18(6):341-50.
    View in: PubMed
    Score: 0.010
  66. Safety of efalizumab in adults with chronic moderate to severe plaque psoriasis: a phase IIIb, randomized, controlled trial. Int J Dermatol. 2006 May; 45(5):605-14.
    View in: PubMed
    Score: 0.010
  67. Efalizumab retreatment in patients with moderate to severe chronic plaque psoriasis. J Am Acad Dermatol. 2006 Apr; 54(4 Suppl 1):S164-70.
    View in: PubMed
    Score: 0.010
  68. Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled Phase III trials: part I. J Cutan Med Surg. 2005 Dec; 9(6):303-12.
    View in: PubMed
    Score: 0.010
  69. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005 Mar; 52(3 Pt 1):425-33.
    View in: PubMed
    Score: 0.009
  70. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol. 2005 Jan; 141(1):31-8.
    View in: PubMed
    Score: 0.009
  71. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol. 2004 Nov-Dec; 3(6):614-24.
    View in: PubMed
    Score: 0.009
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.